<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549508</url>
  </required_header>
  <id_info>
    <org_study_id>CIA 134</org_study_id>
    <nct_id>NCT02549508</nct_id>
  </id_info>
  <brief_title>Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD</brief_title>
  <official_title>Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisher and Paykel Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fisher and Paykel Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to examine the application of AutoCPAP with and without&#xD;
      SensAwake in subjects with OSA and Post-Traumatic Stress Disorder (PTSD), and evaluate&#xD;
      whether patients achieve better sleep quality and compliance with SensAwake, compared to the&#xD;
      same treatment without SensAwake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conceptually, awareness of pressure occurs only during wakefulness. Thus reducing the&#xD;
      pressure during wakefulness may improve therapy comfort and potentially adherence without&#xD;
      compromising therapy efficacy. SensAwake™ is a unique pressure relief technology developed by&#xD;
      Fisher &amp; Paykel Healthcare which detects irregularity in the flow signal indicative of the&#xD;
      transition from sleep to wake. When the transition from sleep to wake is detected the device&#xD;
      promptly reduces the pressure to help facilitate a return to sleep.&#xD;
&#xD;
      It is hypothesised that AutoCPAP with SensAwake will improve patient comfort and compliance&#xD;
      in the PTSD and OSA patients who are naïve to CPAP therapy.&#xD;
&#xD;
      The investigators will not be blinded to the study. The participants will be blinded to the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence (Hours on Therapy)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Hours per night averaged over total time period measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality (Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>Change from Baseline after 4 weeks</time_frame>
    <description>The ESS is a validated questionnaire that assesses an idnviduals likelihood of falling asleep in a variety of given situations (such as having a conversation with someone or stopped a red light while driving.) Each question is given a rating between 0 and 3, with 0 being no chance of falling asleep and 3 being high chance of falling asleep. Answers are then summed together to determine the level of sleepiness an individual is experiencing with a maximum score of 24. The higher the score, the more sleepy the person is. From a clinical perspective an ESS score of 0-10 indicates a normal level sleepiness, a score of 11-14 indicates mild sleepiness, a score of 15-17 indicates moderate sleepiness and a score of 18+ indicates severe sleepiness. Results below are reported as a mean change from baseline in which negative scores indicate reduction in ESS from baseline (less sleepiness). Positive scores indicate increase in ESS from baseline (more sleepiness.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>Change from Baseline after 4 weeks</time_frame>
    <description>ISI; 0-7 = No clinically significant insomnia, 8-14 = Sub threshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). Results reported in mean change from baseline. Negative scores indicate improvement in ISI, positive scores indicate increase in ISI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Obstructive Sleep Apnea (OSA)</condition>
  <condition>Post-Traumatic Stress Disorder (PTSD)</condition>
  <arm_group>
    <arm_group_label>AutoCPAP with SensAwake On, then SenAwake Off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AutoCPAP with SensAwake Off, then SensAwake On</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AutoCPAP with SensAwake On</intervention_name>
    <description>The comfort feature 'SensAwake' will be turned on</description>
    <arm_group_label>AutoCPAP with SensAwake Off, then SensAwake On</arm_group_label>
    <arm_group_label>AutoCPAP with SensAwake On, then SenAwake Off</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AutoCPAP with SensAwake Off</intervention_name>
    <description>The comfort feature 'SensAwake' will be turned off</description>
    <arm_group_label>AutoCPAP with SensAwake Off, then SensAwake On</arm_group_label>
    <arm_group_label>AutoCPAP with SensAwake On, then SenAwake Off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male and female subjects &gt; 18 years Diagnosed with OSA by a practicing sleep physician,&#xD;
        within the last six months Diagnosed with post-traumatic stress disorder as diagnosed by a&#xD;
        behavioral health professional, and quantified by McChord PTSD checklist All races and&#xD;
        ethnicities will be included Naïve to CPAP therapy (has not used CPAP within the last 5&#xD;
        years)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        &lt; 18 years of age if mental status is questionable, the patient will be excluded at the&#xD;
        discretion of the consenting provider Unable/unwilling to follow the directions necessary&#xD;
        for CPAP use Patients contraindicated for CPAP/AutoCPAP, at the discretion of the&#xD;
        consenting provider&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron B Holley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed National Military Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Thomson, MA</last_name>
    <role>Study Chair</role>
    <affiliation>Fisher &amp; Paykel Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <results_first_submitted>July 2, 2020</results_first_submitted>
  <results_first_submitted_qc>October 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 10, 2020</results_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02549508/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AutoCPAP With SensAwake On First, Then SensAwake Off</title>
          <description>Randomized participants in this group will experience SensAwake On first while using AutoCPAP for the first 4 weeks of the intervention.&#xD;
After 4 weeks, participants will cross over to the opposite arm and complete 4 weeks with SensAwake off while using AutoCPAP.</description>
        </group>
        <group group_id="P2">
          <title>AutoCPAP With SensAwake Off First, Then SensAwake On</title>
          <description>Randomized participants in this group will experience SensAwake Off first while using AutoCPAP for the first 4 weeks of the intervention.&#xD;
After 4 weeks, participants will cross over to the opposite arm and complete 4 weeks with SensAwake on while using AutoCPAP.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AutoCPAP With SensAwake On First, Then SensAwake Off</title>
          <description>Randomized participants in this group will experience SensaAwake On first while using AutoCPAP for the first 4 weeks of the intervention.&#xD;
After 4 weeks, participants will cross over to the opposite arm and complete 4 weeks with SensAwake off while using AutoCPAP.</description>
        </group>
        <group group_id="B2">
          <title>AutoCPAP With SensAwake Off First, Then SensAwake On</title>
          <description>Randomized participants in this group will experience SensaAwake Off first while using AutoCPAP for the first 4 weeks of the intervention.&#xD;
After 4 weeks, participants will cross over to the opposite arm and complete 4 weeks with SensAwake On while using AutoCPAP.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="8.0"/>
                    <measurement group_id="B2" value="37.7" spread="8.6"/>
                    <measurement group_id="B3" value="37.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                    <count group_id="B2" value="38"/>
                    <count group_id="B3" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adherence (Hours on Therapy)</title>
        <description>Hours per night averaged over total time period measured.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AutoCPAP With SensAwake On</title>
            <description>Analysis of all participants who completed the AutoCPAP with SensAwake on arm.</description>
          </group>
          <group group_id="O2">
            <title>AutoCPAP With SensAwake Off First</title>
            <description>Analysis of all participants who completed the AutoCPAP with SensAwake off arm</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence (Hours on Therapy)</title>
          <description>Hours per night averaged over total time period measured.</description>
          <units>Hours/night</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="1.1" upper_limit="4.8"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality (Epworth Sleepiness Scale (ESS)</title>
        <description>The ESS is a validated questionnaire that assesses an idnviduals likelihood of falling asleep in a variety of given situations (such as having a conversation with someone or stopped a red light while driving.) Each question is given a rating between 0 and 3, with 0 being no chance of falling asleep and 3 being high chance of falling asleep. Answers are then summed together to determine the level of sleepiness an individual is experiencing with a maximum score of 24. The higher the score, the more sleepy the person is. From a clinical perspective an ESS score of 0-10 indicates a normal level sleepiness, a score of 11-14 indicates mild sleepiness, a score of 15-17 indicates moderate sleepiness and a score of 18+ indicates severe sleepiness. Results below are reported as a mean change from baseline in which negative scores indicate reduction in ESS from baseline (less sleepiness). Positive scores indicate increase in ESS from baseline (more sleepiness.)</description>
        <time_frame>Change from Baseline after 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AutoCPAP With SensAwake On</title>
            <description>Analysis of all participants who completed the AutoCPAP with SensAwake on arm</description>
          </group>
          <group group_id="O2">
            <title>AutoCPAP With SensAwake Off</title>
            <description>Analysis of all participants who completed the AutoCPAP with SensAwake off arm</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality (Epworth Sleepiness Scale (ESS)</title>
          <description>The ESS is a validated questionnaire that assesses an idnviduals likelihood of falling asleep in a variety of given situations (such as having a conversation with someone or stopped a red light while driving.) Each question is given a rating between 0 and 3, with 0 being no chance of falling asleep and 3 being high chance of falling asleep. Answers are then summed together to determine the level of sleepiness an individual is experiencing with a maximum score of 24. The higher the score, the more sleepy the person is. From a clinical perspective an ESS score of 0-10 indicates a normal level sleepiness, a score of 11-14 indicates mild sleepiness, a score of 15-17 indicates moderate sleepiness and a score of 18+ indicates severe sleepiness. Results below are reported as a mean change from baseline in which negative scores indicate reduction in ESS from baseline (less sleepiness). Positive scores indicate increase in ESS from baseline (more sleepiness.)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4.5"/>
                    <measurement group_id="O2" value="-3.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insomnia Severity Index (ISI)</title>
        <description>ISI; 0-7 = No clinically significant insomnia, 8-14 = Sub threshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). Results reported in mean change from baseline. Negative scores indicate improvement in ISI, positive scores indicate increase in ISI.</description>
        <time_frame>Change from Baseline after 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AutoCPAP With SensAwake On</title>
            <description>Analysis of all participants who completed the AutoCPAP with SensAwake on arm</description>
          </group>
          <group group_id="O2">
            <title>AutoCPAP With SensAwake Off</title>
            <description>Analysis of all participants who completed the AutoCPAP with SensAwake off arm</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index (ISI)</title>
          <description>ISI; 0-7 = No clinically significant insomnia, 8-14 = Sub threshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). Results reported in mean change from baseline. Negative scores indicate improvement in ISI, positive scores indicate increase in ISI.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.5"/>
                    <measurement group_id="O2" value="-4.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AutoCPAP With SensAwake On</title>
          <description>Includes data for all participants who were exposed at any point of the 8 week study to SensAwake On. Due to drop outs, not all participants were exposed to this intervention.</description>
        </group>
        <group group_id="E2">
          <title>AutoCPAP With SensAwake Off</title>
          <description>Includes data for all participants who were exposed at any point of the 8 week study to SensAwake Off. Due to drop outs, not all participants were exposed to this intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Scientist</name_or_title>
      <organization>Fisher &amp; Paykel Healthcare</organization>
      <phone>+64 09 574 0100 ext 7044</phone>
      <email>CPAPtrial@fphcare.co.nz</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

